Business
Aelis Farma: Availability of the 2025 Half-Year Financial Report
BORDEAUX, France, September 25, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that its 2025 half-year financial report has been made available to the public and filed with the French Financial Markets Authority (Autorité des marchés financiers).
About this update from Aelis Farma Sa
[{"type":"text","content":"BORDEAUX, France, September 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":71,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces that its 2025 half-year financial report has been made available to the public and filed with the French Financial Markets Authority (Autorité des marchés financiers).","length":384,"tagName":"p"},{"type":"text","content":"It can be consulted on the Company's website, www.aelisfarma.com, in the section Investors/Documentation/Reports.","length":117,"tagName":"p"},{"type":"text","content":"About AELIS FARMA","length":17,"tagName":"p"},{"type":"text","content":"Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company’s CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.","length":770,"tagName":"p"},{"type":"text","content":"Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB1-SSi in humans. The Company also has a portfolio of new innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor, including diseases involving peripheral organs, such as obesity and related met...